MYD.F Myriad Genetics Inc

Healthcare Biotechnology Frankfurt Exchange
5.04 EUR
Close of Nov 13, 2026
2.45 6.80
Market cap
EUR 484M
P/E
-
P/B
1.99x
ROE
-65.3%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Sep 2026.

Is MYD.F undervalued?

Graham number

The Graham number of Myriad Genetics Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Myriad Genetics Inc fundamental analysis

No fundamental analysis for Myriad Genetics Inc yet.

Myriad Genetics Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Myriad Genetics Inc

Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. It offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected delet…

Full company profile